Literature DB >> 27068527

In Vitro and Ex Vivo Evaluations of Lipid Anti-Cancer Nanoformulations: Insights and Assessment of Bioavailability Enhancement.

Ankitkumar S Jain1, Vivek V Dhawan1, Bruno Sarmento2, Mangal S Nagarsenker3.   

Abstract

Lipid-based nanoformulations have been extensively investigated for improving oral efficacy of plethora of drugs. Chemotherapeutic agents remain a preferred option for effective management of cancer; however, most chemotherapeutic agents suffer from limitation of poor oral bioavailability that is associated with their physicochemical properties. Drug delivery via lipid-based nanosystems possesses strong rational and potential for improving oral bioavailability of such anti-cancer molecules through various mechanisms, viz. improving their gut solubilisation owing to micellization, improving mucosal permeation, improving lymphatic uptake, inhibiting intestinal metabolism and/or inhibiting P-glycoprotein efflux of molecules in the gastrointestinal tract. Various in vitro characterization techniques have been reported in literature that aid in getting insights into mechanisms of lipid-based nanodevices in improving oral efficacy of anti-cancer drugs. The review focuses on different characterization techniques that can be employed for evaluation of lipid-based nanosystems and their role in effective anti-cancer drug delivery.

Entities:  

Keywords:  bioavailability; ex vivo; in vitro; lipid; nanosystems

Mesh:

Substances:

Year:  2016        PMID: 27068527     DOI: 10.1208/s12249-016-0522-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  1 in total

1.  The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study.

Authors:  Cuicui Zhang; Jianchun Duan; Zhen He; Li Yang; Sen Yang; Zhe Zhang; Yang Liu; Rui Wan; Lin Lin; Xuan Wu; Wei Wang; Qiming Wang; Jie Wang
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.